Compare Stocks: SLRN, TBPH, ACHV, and GYRE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHV Achieve Life Sciences	$7.07 -2.9%	$7.04	$2.62 ▼ $8.64	$727.50M	2.25	1.34 million shs	1.46 million shs
GYRE Gyre Therapeutics	$6.74	$6.52	$5.44 ▼ $9.42	$751.58M	1.92	86,960 shs	69,802 shs
SLRN Acelyrin	$2.27	$2.27	$1.95 ▼ $2.66	$229.17M	1.07	1.09 million shs	N/A
TBPH Theravance Biopharma	$17.01 -0.1%	$16.95	$13.08 ▼ $21.03	$883.14M	0.25	560,755 shs	420,492 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHV Achieve Life Sciences	-3.45%	-12.39%	+7.53%	+31.88%	+121.95%
GYRE Gyre Therapeutics	-3.02%	+4.66%	+1.51%	+13.66%	-17.50%
SLRN Acelyrin	0.00%	0.00%	0.00%	0.00%	0.00%
TBPH Theravance Biopharma	-0.23%	-0.35%	+0.59%	+2.28%	+24.78%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHV Achieve Life Sciences	$7.07 -2.9%	$7.04	$2.62 ▼ $8.64	$727.50M	2.25	1.34 million shs	1.46 million shs
GYRE Gyre Therapeutics	$6.74	$6.52	$5.44 ▼ $9.42	$751.58M	1.92	86,960 shs	69,802 shs
SLRN Acelyrin	$2.27	$2.27	$1.95 ▼ $2.66	$229.17M	1.07	1.09 million shs	N/A
TBPH Theravance Biopharma	$17.01 -0.1%	$16.95	$13.08 ▼ $21.03	$883.14M	0.25	560,755 shs	420,492 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHV Achieve Life Sciences	-3.45%	-12.39%	+7.53%	+31.88%	+121.95%
GYRE Gyre Therapeutics	-3.02%	+4.66%	+1.51%	+13.66%	-17.50%
SLRN Acelyrin	0.00%	0.00%	0.00%	0.00%	0.00%
TBPH Theravance Biopharma	-0.23%	-0.35%	+0.59%	+2.28%	+24.78%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHV Achieve Life Sciences	3.00	Buy	$15.00	112.16% Upside
GYRE Gyre Therapeutics	1.67	Reduce	$16.00	137.39% Upside
SLRN Acelyrin	0.00	N/A	N/A	N/A
TBPH Theravance Biopharma	2.00	Hold	$19.40	14.05% Upside

Current Analyst Ratings Breakdown

Latest SLRN, TBPH, ACHV, and GYRE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/7/2026	TBPH Theravance Biopharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/19/2026	ACHV Achieve Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/18/2026	GYRE Gyre Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/17/2026	TBPH Theravance Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/13/2026	ACHV Achieve Life Sciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$13.00
8/12/2026	ACHV Achieve Life Sciences	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$18.00
8/12/2026	ACHV Achieve Life Sciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/12/2026	ACHV Achieve Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
8/7/2026	GYRE Gyre Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/7/2026	TBPH Theravance Biopharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/3/2026	TBPH Theravance Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)

(Data available from 9/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	$0.40 per share	N/A
GYRE Gyre Therapeutics	$109.82M	6.84	$0.22 per share	31.28	$1.48 per share	4.55
SLRN Acelyrin	N/A	N/A	N/A	N/A	$6.74 per share	N/A
TBPH Theravance Biopharma	$104.31M	8.47	N/A	N/A	$5.86 per share	2.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHV Achieve Life Sciences	-$54.65M	-$1.55	N/A	N/A	N/A	N/A	-511.12%	-82.35%	11/5/2026 (Estimated)
GYRE Gyre Therapeutics	$5.03M	-$0.21	N/A	N/A	N/A	-15.47%	-6.57%	-5.35%	11/6/2026 (Estimated)
SLRN Acelyrin	-$381.64M	-$2.69	N/A	N/A	N/A	N/A	-44.12%	-39.02%	N/A
TBPH Theravance Biopharma	$105.89M	$1.01	16.84	21.00	N/A	51.58%	-0.77%	-0.46%	11/10/2026 (Estimated)

Latest SLRN, TBPH, ACHV, and GYRE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ACHV Achieve Life Sciences	-$0.1649	-$0.80	-$0.6351	-$0.80	N/A	N/A
8/10/2026	Q2 2026	TBPH Theravance Biopharma	$0.0725	-$0.11	-$0.1825	-$0.11	$22.49 million	$20.73 million
8/7/2026	Q2 2026	GYRE Gyre Therapeutics	-$0.0567	-$0.12	-$0.0633	-$0.12	$26.49 million	$29.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	N/A
GYRE Gyre Therapeutics	N/A	N/A	N/A	N/A	N/A
SLRN Acelyrin	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHV Achieve Life Sciences	0.87	0.95	0.95
GYRE Gyre Therapeutics	N/A	4.26	3.86
SLRN Acelyrin	N/A	7.15	7.15
TBPH Theravance Biopharma	N/A	13.54	13.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHV Achieve Life Sciences	33.52%
GYRE Gyre Therapeutics	23.99%
SLRN Acelyrin	87.31%
TBPH Theravance Biopharma	99.10%

Insider Ownership

Company	Insider Ownership
ACHV Achieve Life Sciences	1.80%
GYRE Gyre Therapeutics	9.50%
SLRN Acelyrin	13.60%
TBPH Theravance Biopharma	7.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHV Achieve Life Sciences	20	102.90 million	101.05 million	Optionable
GYRE Gyre Therapeutics	40	111.51 million	100.92 million	No Data
SLRN Acelyrin	135	100.95 million	86.68 million	No Data
TBPH Theravance Biopharma	110	51.92 million	47.95 million	Optionable

SLRN, TBPH, ACHV, and GYRE Headlines

Recent News About These Companies

Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue?

September 9 at 12:31 PM | zacks.com

Theravance Biopharma (NASDAQ:TBPH) Downgraded by Zacks Research to "Hold"

September 9 at 7:05 AM | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above Fifty Day Moving Average - Time to Sell?

September 9 at 3:59 AM | marketbeat.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Average Rating of "Hold" by Brokerages

September 2, 2026 | americanbankingnews.com

Theravance Biopharma, Inc. $TBPH is Newtyn Management LLC's 2nd Largest Position

August 31, 2026 | marketbeat.com

Bank of America Corp DE Raises Position in Theravance Biopharma, Inc. $TBPH

August 31, 2026 | marketbeat.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Short Interest Update

August 28, 2026 | marketbeat.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Rating of "Hold" by Analysts

August 28, 2026 | marketbeat.com

Theravance Biopharma Inc

August 20, 2026 | money.usnews.com

TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders

August 15, 2026 | businesswire.com

Wedge Capital Management L L P NC Buys Shares of 128,845 Theravance Biopharma, Inc. $TBPH

August 15, 2026 | marketbeat.com

TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks

August 11, 2026 | zacks.com

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 10, 2026 | prnewswire.com

Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results

August 6, 2026 | financialpost.comF

Theravance Biopharma Stock Dividends | NASDAQ:TBPH | Benzinga

July 13, 2026 | benzinga.com

Theravance Biopharma (NASDAQ:TBPH) Major Shareholder Sells $428,712.51 in Stock

July 2, 2026 | insidertrades.com

Theravance Stock Down 3% After Zymeworks Announces Buyout

June 30, 2026 | zacks.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH)

June 29, 2026 | prnewswire.com

TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders

June 29, 2026 | businesswire.com

Shareholder Alert: Ademi LLP investigates whether Theravance Biopharma, Inc. is obtaining a Fair Price for Public Shareholders

June 29, 2026 | prnewswire.com

Theravance Biopharma, Inc.: Theravance Biopharma Enters Into Definitive Agreement To Be Acquired By Zymeworks For $17.00 Per Share In Cash Plus A Contingent Value Right

June 29, 2026 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLRN, TBPH, ACHV, and GYRE Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

$7.07 -0.21 (-2.88%)

Closing price 04:00 PM Eastern

Extended Trading

$7.06 0.00 (-0.07%)

As of 05:04 PM Eastern

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

Gyre Therapeutics NASDAQ:GYRE

$6.74 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$6.72 -0.02 (-0.22%)

As of 04:10 PM Eastern

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Acelyrin NASDAQ:SLRN

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

Theravance Biopharma NASDAQ:TBPH

$17.01 -0.01 (-0.06%)

Closing price 04:00 PM Eastern

Extended Trading

$17.02 +0.00 (+0.03%)

As of 04:10 PM Eastern

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLRN, TBPH, ACHV, and GYRE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLRN, TBPH, ACHV, and GYRE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLRN, TBPH, ACHV, and GYRE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLRN, TBPH, ACHV, and GYRE Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

Gyre Therapeutics NASDAQ:GYRE

Acelyrin NASDAQ:SLRN

Theravance Biopharma NASDAQ:TBPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLRN, TBPH, ACHV, and GYRE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLRN, TBPH, ACHV, and GYRE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLRN, TBPH, ACHV, and GYRE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLRN, TBPH, ACHV, and GYRE Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

Gyre Therapeutics NASDAQ:GYRE

Acelyrin NASDAQ:SLRN

Theravance Biopharma NASDAQ:TBPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools